Practice Management News

Odevixibat treatment reduced levels of peripheral blood autotaxin, pruritus and serum bile acid among pediatric patients with progressive familial intrahepatic cholestasis, according to pooled data.

To streamline and validate diagnosis of and clinical trials in non-alcoholic steatohepatitis, one group is on a mission to determine the best non-invasive tests for all physicians to use, according to a presentation.

Tenofovir alafenamide therapy was safe, well-tolerated and prevented the transmission of hepatitis B virus from pregnant mothers to infants, according to research presented at The Liver Meeting Digital Experience.

Based on the current number of cases of non-alcoholic steatohepatitis in the United States, more than $175 billion will be spent on managing and treating the disease, two-thirds being spent in those with obesity and NASH, according to a presentation.

In a video exclusive, Marlyn Mayo, MD, of the University of Texas Southwestern Medical Center, reported long-term treatment with seladelpar was safe and well-tolerated in reducing markers of cholestasis and hepatocellular injury.

Compared to current practices of annual screening for hepatitis C virus in men who have sex with men, working toward reducing their risk and screening every 6 months could prove cost effective, according to a presentation.

Data used well via artificial intelligence and transparent algorithms offers health care a glimpse into democratization and equitable, efficient and efficacious care, according to an expert speaking at The Liver Meeting Digital Experience.

Higher end-of-treatment hepatitis B e-antigen level correlated with nucleos(t)ide clinical relapse but did not correlate with relapse severity regardless of HBsAg level among patients with chronic hepatitis B virus, according to research.

More than 40% of hepatology providers said burnout during the COVID-19 negatively impacted their well-being, including work fulfillment and satisfaction, according to a presentation at The Liver Meeting Digital Experience.

Geisinger Health System is working to develop a tool that it said will dramatically lower the time it takes to diagnose rare conditions with a genetic cause.